Congo competition in 2016. Her career continued to flourish, with appearances in commercials for major local brands such as Vodacom, Ecobank, Betasol, and Beviour hotel and winning the award for best runway model at Afrifamu in 2020 in Los Angeles.
But Anado's talents don't stop there. In addition to her successful modeling career, she is also a talented singer-rapper and actress. Her love for music comes from her cultural background and the many talented artists and singers surrounding her. She is excited to finally release her single and share her talents with the world.
Despite her many successes, Anado has faced her share of challenges. She struggled to convince her family of her many different passions and has had to work hard to achieve her goals. In 2019, she flew to the United States to pursue her dreams, starting from scratch and continuing to work hard.
Anado's future goals are to become a successful model and one of the best artists in the world. In addition to her career aspirations, she is also an active philanthropist, having started her NGO "Heart of Africa" to help raped women, mothers, and young people who have no support to realize their dreams. She is determined to inspire African youth through her personal history of hard work, perseverance, and consistency. She encourages others to believe in their dreams and be willing to start over and have new beginnings.
She is a true inspiration and is determined to be a voice for social change in her community. Follow Anado's journey on Instagram, Facebook, Twitter, and YouTube, and stay tuned for her upcoming projects.
Anado Kabika is more than just a model, singer-rapper, and actress; she is a true force for change. With her powerful voice and unwavering determination to succeed, Anado inspires young people everywhere. Don't miss her second single release on January 20th, 2023.
Celebrate the connection between grandparents and children with the best-selling How to Babysit a Grandma or Grandpa Book. Adorable illustrations in the board book will grab the attention of your little one while they receive sage advice. The Grandma book features sections on how to keep a grandma busy, things to do at the park, possible places to sleep and what to do once you're both tucked in for the night. Written in a how-to style, the narrator in the Grandpa book gives tips for "babysitting" a grandpa, including what to eat for snack, what to do on a walk and how to play with him.Extension of Tablo TrEatmeNt Duration (XTEND) study: successful 24 h prolonged therapy with Tablo in critical patients

Background The Tablo® Hemodialysis System (Tablo) is an all in one, easy-to-learn device featuring integrated water purification, on demand dialysate production and two-way wireless data transmission and is approved for use in the acute, chronic, and home settings. Prior reports have demonstrated Tablo’s ability to achieve clinical goals, seamlessly integrate into hospitals and reduce cost across a wide range of treatment times. Extension of the Tablo cartridge to 24 h allows prolonged therapy and even greater flexibility for prescribers in the acute setting. The objective is to report on the first ever experience with Tablo prolonged therapy between 12 and 24 h in critically ill patients treated at a single-center ICU. Methods Nursing staff were trained during a single training session on Tablo prolonged therapy. After a run-in period of five treatments, Tablo data were collected via real-time transmission to a cloud-based, HIPAA compliant platform and reviewed by site staff. Dialysis treatment delivery, clinically significant alarms, and clotting events were recorded. Sub-group analysis between COVID-19 positive and negative patients were reported. Results One hundred (100) consecutive Tablo prolonged treatments had a median prescribed treatment time of 24 h and a median achieved treatment time of 21.3 h. Median cartridge usage was 1.3 per treatment. The dialysis treatment time was delivered in 91% of treatments, with 6% ending early due to an alarm, and 3% ending due to clotting. Clinically significant alarms occurred at a median rate of 0.5 per treatment hour with a resolution time of 18 s. Median blood pump stoppage time related to these alarms was 2.3 min per treatment. Blood pump stoppage time was higher in the COVID-19 subgroup when compared to the non-COVID-19 subgroup. Conclusion Tablo successfully achieves prescribed treatment time with minimal therapy interruptions from alarms or cartridge changes. This data demonstrates the effectiveness of Tablo in achieving personalization of treatments necessary for unstable patients and enabling successful delivery of extended therapy with minimal clotting. Tablo’s prolonged therapy meets the needs of critically patients, including COVID-19 positive patients, requiring renal replacement therapy for greater than 12 h.


Introduction
Renal replacement therapy (RRT) is often required to treat critically ill patients with acute kidney injury (AKI) or end-stage kidney disease (ESKD) in the intensive care Open Access *Correspondence: csilva@outsetmedical.com 2 Outset Medical, San Jose, USA Full list of author information is available at the end of the article unit (ICU) [1,2]. AKI occurs in up to half of all patients admitted to the ICU, and of these patients, 4-13% require RRT [1,3]. While there are various RRT modalities available, including continuous, prolonged, and intermittent, meta-analyses have demonstrated minimal differences in clinical outcomes between these modalities [4]. However, ICU clinicians typically favor treatments of greater than 12 h for hemodynamically unstable patients [5][6][7], as they allow for more gradual fluid removal and solute clearance over the course of the treatments [5,8].
The same severe illness that leads to the need for a prolonged therapy often results in organ failure beyond AKI; further complicating the treatment regimen with other critical lifesaving devices, such as mechanical ventilation and extracorporeal membrane oxygenation (ECMO) therapy, that can lead to interdevice interaction and competition for vascular access [9,10]. Prolonged therapy is frequently administered concurrently with ECMO, either independently or integrated into the circuit, to mitigate hemodynamic instability and fluid imbalance [11] presenting a highly complex and labor-intensive treatment regimen.
The acuity of these patients, combined with the increased treatment time and slower blood flow rate, adds complexity to the effective delivery of prolonged therapies. The most common complication is associated with circuit clotting or clogging. Clotting in the filter or extracorporeal circuit may be exacerbated by compromised or inadequate vascular access [12]. Poor catheter function may trigger arterial and venous pressure alarms which stagnate extracorporeal blood flow, leading to increased blood pump stoppage that exacerbate clotting events [5,13]. During the pandemic, the risk of clotting or clogging the circuit during prolonged therapies was further increased in COVID-19 positive patients with AKI due to the prothrombotic state induced by the disease process [14]. Clotting and clogging of the extracorporeal circuit can have significant impact on the ability to achieve ultrafiltration and metabolic clearance targets due to treatment interruptions. In addition to the risk of failing to achieve clinical goals, these interruptions drive up the cost of care due to increased supply utilization from repeated system set up [15], and create additional work for an already highly burdened critical care nursing staff [16].
Taken together and compounded by the staffing shortages that have resulted from the COVID-19 pandemic, there is a critical need for simple, flexible RRT technology that can deliver effective therapy with minimal treatment interruption. The Tablo ® Hemodialysis System ("Tablo" or "Tablo System") is a novel FDA approved allin-one system capable of purifying water and producing dialysate on demand in any environment, from the ICU to home. It consists of a console and a single use, disposable extracorporeal circuit (the Tablo Cartridge) for hemodialysis. Tablo is compatible with most commercially available high-flux dialyzers and can perform hemodialysis, isolated ultrafiltration, or sequential, mixed-mode treatments without the need for external water purification devices or sterile bags of dialysate.
Tablo can deliver dialysis therapy across a wide range of blood and dialysate flow rates on a single cartridge up to 24 h. The aim of the Extension of Tablo Treatment Duration ("XTEND") study was to provide the first ever report of treatment experience, cartridge utilization, and clotting events in critically ill patients prescribed treatments between 12 and 24 h using the Tablo System.

Study design and patient eligibility
An observational, retrospective, post-market study was conducted at St. Mark's Hospital (Salt Lake City, UT, USA) over a 9-month period between January 2021 and September 2021 to report on the first 100 consecutive treatments performed beyond 12 h on the Tablo system. The study was reviewed and approved by the Advarra Institutional Review Board (IRB) as the IRB of record (Pro00049220). In accordance with IRB guidance, a waiver of informed consent was granted, as the standard of care encompasses the study intervention. Hospital staff underwent standard training performed by Outset Medical, Inc. ("Outset") personnel on prescribing, setup and management of the Tablo console.
After an initial run-in period at the facility of five Tablo treatments greater than 12 h, all consecutive treatments were screened for eligibility. All patients who were hospitalized in the ICU with ESKD or AKI and requiring dialysis were screened for eligibility. Inclusion criteria consisted of patients who weighed 34 kgs or greater and were prescribed RRT for greater than 12 h utilizing Tablo.

Procedures and data collection
Demographic information, sequential organ failure